On October 2, the Federal Circuit issued a non-precedential decision affirming a PTAB final written decision that invalidated all claims of a Pioneer Hi-Bred International, Inc. (“Pioneer”) patent for lack of enablement. The PTAB rejected claims 1-33 of the U.S. Patent No. 11,371,055 (’055 patent) directed to
Novartis entered into a global licensing agreement with Suzhou-based Abogen Biosciences on October 2 to develop ABO2203, an investigational mRNA therapy, to complement the Swiss pharma’s treatments for autoimmune diseases. The deal also includes an exclusive option agreement to license other next-generation therapies developed on Abogen’s mRNA platform.
Multispecific antibodies have emerged as a promising class of cancer immunotherapeutics to target multiple epitopes for improved tumor selectivity and clinical efficacy. Bispecific and trispecific antibodies are engineered to contain two and three binding sites, respectively, allowing them to engage multiple cell types to trigger a more precise and thorough
On Aug. 25, USPTO designated a PTAB decision in Ex parte Chowdhury (Appeal No. 2025-002261) issued in February as informative. The decision concerns the Board’s reversal of an Examiner’s rejection of claims based on improper inclusion of structurally diverse microRNAs (miRNAs) in a Markush group. The patent application
IP litigation between 10x Genomics and Parse Biosciences in single-cell sequencing turned on Aug 28, when a Delaware jury found that Parse’s Evercode Whole Transcriptome products willfully infringed three Roche-originating patents exclusively licensed to Scale Biosciences ruled, which 10x Genomics acquired in 2025. The verdict came just nine days
On Aug 6, 2026, an Appeals Review Panel (ARP) in Ex parte Baurin reversed a PTAB decision and reinstated the examiner’s obviousness-type double patenting (ODP) rejection solely based on the anti-harassment rationale even absent an improper extension of patent term. The application at issue (17/135,529, the ’529
Merck and Moderna announced success with their jointly developed intismeran autogene (intismeran), a personalized mRNA-based cancer vaccine, in combination with KEYTRUDA (pembrolizumab), an anti-PD-1 immunotherapy, in preventing the remission and spread of melanoma based on positive top-line results from the Phase 3 INTerpath-001 trial. The trial result marks a groundbreaking
Felzartamab, an anti-CD38 monoclonal antibody, developed by MorphoSys now acquired by Novartis has won its first global approval in China for treating multiple myeloma (MM) in combination with lenalidomide and dexamethasone in adults who have received at least one prior line of therapy. Human Immunology Bioscences (HI-Bio) obtained exclusive licensing
Curium has entered a definitive agreement to acquire Lantheus in a deal worth up to $8 billion. Curium develops, manufactures, and supplies of radiopharmaceuticals used in diagnosing and treating cancer. The company holds patents on the compositions, formulations, purification processes, and systems and methods of use of radioactive isotope of
The Federal Circuit vacated a PTAB final written decision on an inter partes review (IPR) in which Dental Monitoring SAS’s (“Dental Monitoring”) patent directed to a method for acquiring and analyzing an image of a dental arch had been invalidated as obvious. Align Technology, Inc. (“Align”) filed a petition
Replimune's Tudriqev granted accelerated approval after two setbacks FDA granted accelerated approval to Replimune’s melanoma therapy, Tudriqev (previously known as RP1) in combination with Bristol Myers Squibb’s Opdivo (nivolumab) in adult patients who experienced tumor progression despite prior anti-PD-1 therapy. Tudriqev (vusolimogene oderparepvec-wtpg) is a oncolytic
On June 4, 2026, Justice Jackson wrote for a unanimous Court reversing the Federal Circuit, holding Amarin failed to plausibly allege that Hikma actively induced infringement through its generic. NDA, ANDA, and “Skinny Labels” Pharmaceutical companies usually submit a new drug application (NDA) to the FDA with full data on